Review
Copyright ©The Author(s) 2020.
World J Gastroenterol. Sep 14, 2020; 26(34): 5074-5089
Published online Sep 14, 2020. doi: 10.3748/wjg.v26.i34.5074
Figure 2
Figure 2 Metabolic enzyme mutations lead to the accumulation of oncometabolites, which competitively inhibit α-ketoglutarate-dependent dioxygenases. α-KG: α-ketoglutarate; AMLs: Acute myeloid leukemias; D-2HG: D-2-hydroxyglutarate; FH: Fumarate hydrase; HLRCC: Hereditary leiomyomatosis and renal cell cancer; IDH: Isocitrate dehydrogenase; LGGs: Low-grade gliomas; SDH: Succinate dehydrogenase.